Article

Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study

Kona Chowdhury 1, Mainul Haque 2,*, Nadia Nusrat 3, Nihad Adnan 4,*, Saleql Islam 4,*, Afzalunnessa Binte Lutfor 5, Dilara Begum 6, Arif Rabbany 7, Enamul Karim 8,*, Abdul Malek 9,*, Nasim Jahan 10,*, Jesmine Akter 11,*, Sumala Ashraf 12,*, Mohammad Nazmul Hasan 13,*, Mahmuda Hassan 14,*, Najnin Akhter 15,*, Monika Mazumder 16, Nazmus Sihan 17,*, Nurun Naher 18,*, Shaheen Akter 18,*, Sifat Uz Zaman 19,*, Tanjina Chowdhury 20,*, Jebun Nesa 21,*, Susmita Biswas 21,*, Mohammad Didarul Islam 22,*, Al Mamun Hossain 23,*, Habibur Rahman 24,*, Palash Kumar Biswas 25,*, Mohammed Shaheen 26,*, Farah Chowdhury 26,*, Santosh Kumar 27,*, Amanj Kurdi 28,*, Zia Ul Mustafa 31,*, Natalie Schellack 32,*, Marshall Gowere 32,*, Johanna C. Meyer 33,*, Sylvia Opana 34 and Brian Godman 28,*,35,*.©

Department of Paediatrics, Gonoshasthaya Samaj Vittik Medical College and Hospital, Savar, Dhaka 1344, Bangladesh; konachy56@yahoo.com
1 Department of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia
2 Department of Paediatrics, Delta Medical College and Hospital, 26/2, Principal Abul Kashem Road, Mirpur-1, Dhaka 1216, Bangladesh; nuratnadia.ns@gmail.com
3 Department of Microbiology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; nihad@juniv.edu (N.A.); salequl@juniv.edu (S.I.); sifat.zaman9@gmail.com (S.U.Z.)
4 Department of Microbiology, Ad-Din Women’s Medical College, 2 Boro Mogbazar, Dhaka 1217, Bangladesh; lizablutfor@gmail.com
5 Department of Paediatrics, Dhaka Medical College Hospital, 100 Ramna Central Shaheed Minar Area, Bakshi Bazar, Dhaka 1000, Bangladesh; dr.dilara123@gmail.com
6 Department of Paediatrics, Mymensnigh Medical College Hospital, Dhaka-Mymensingh Road, Mymensingh Sadar, Mymensingh 2200, Bangladesh; arifdrmmc@gmail.com
7 Department of Paediatrics, US-Bangla Medical College, Kornogop, Tarabgo, Rupganj, Narayangonj 1460, Bangladesh; drenamul@gmail.com
8 Department of Paediatrics, Green Life Medical College Hospital, Dhaka 1205, Bangladesh; malekabdul003@yahoo.com
9 Department of Paediatrics, Agsar Ali Hospital, Distillery Road, Ganderia, Dhaka 1204, Bangladesh; njahan.jesy@gmail.com
10 Department of Paediatrics, Bangladesh Specialized Hospital, Mirpur Road, Dhaka 1207, Bangladesh; Jamitu@gmail.com
11 Department of Paediatrics, Holy Family Red Crescent Medical College Hospital, 1-Eskaton Garden Road, Dhaka 1000, Bangladesh; sumalaashraf@yahoo.com
12 Department Paediatric Surgery, Cumilla Medical College Hospital, Cumilla 3500, Bangladesh; montybich@gmail.com
13 Department of Paediatrics, Ad-din Women’s Medical College, 2 Boro Mogbazar, Dhaka 1217, Bangladesh; mahmudahasn@yahoo.com
14 Department of Paediatrics, Cumilla Medical College Hospital, Cumilla 3500, Bangladesh; najninakhter114517@gmail.com (N.A.); dr.sihan@gmail.com (N.S.)
15 Department of Paediatrics, Rangpur Medical College, Rangpur 5400, Bangladesh; monikams26@yahoo.com
16 Department of Paediatrics, Evercare Hospital, Plot-81, Block-E, Bashundhara Residential Area, Dhaka 1229, Bangladesh; nahernurun004@gmail.com
17 Department of Paediatrics, Enam Medical College and Hospital, Savar, Dhaka 1340, Bangladesh; shaheenssr7@gmail.com
18 Department of Paediatrics, Sylhet M.A.G. Osmani Medical College Hospital, Medical College Road, Kajolshah, Sylhet 3100, Bangladesh; tanjina0407@gmail.com
19 Department of Paediatrics, Center for Women and Child Health, Savar, Dhaka 1349, Bangladesh; drjebunnesa@yahoo.com

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Citation: Chowdhury, K.; Haque, M.; Nusrat, N.; Adnan, N.; Islam, S.; Lutfor, A.B.; Begum, D.; Rabbany, A.; Karim, E.; Malek, A.; et al. Management of Children Admitted to Hospitals across Bangladesh with Suspected or Confirmed COVID-19 and the Implications for the Future: A Nationwide Cross-Sectional Study. Antibiotics 2022, 11, 105. https://doi.org/10.3390/antibiotics11010105

Academic Editors: Soos Gyöngyvér and Masafumi Seki

Received: 1 December 2021
Accepted: 11 January 2022
Published: 14 January 2022

Copyright: © 2022 by the authors. License MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Abstract: There is an increasing focus on researching children admitted to hospital with new variants of COVID-19, combined with concerns about hyperinflammatory syndromes and the overuse of antimicrobials. Paediatric guidelines have been produced in Bangladesh to improve their care. Consequently, the objective is to document the management of children with COVID-19 among 24 hospitals in Bangladesh. Key outcome measures included the percentage prescribed different antimicrobials, adherence to paediatric guidelines and mortality rates using purposely developed report forms. The majority of 146 admitted children were aged 5 years or under (62.3%) and were boys (58.9%). Reasons for admission included fever, respiratory distress and coughing; 86.3% were prescribed antibiotics, typically parenterally, on the WHO ‘Watch’ list, and empirically (98.4%). There were no differences in antibiotic use whether hospitals followed paediatric guidance or not. There was no prescribing of antimalarials and limited prescribing of antivirals (5.5% of children) and antiparasitic medicines (0.7%). The majority of children (92.5%) made a full recovery. It was encouraging to see the low hospitalisation rates and limited use of antimalarials, antivirals and antiparasitic medicines. However, the high empiric use of antibiotics, alongside limited switching to oral formulations, is a concern that can be addressed by instigating the appropriate programmes.

Keywords: antibiotics; antimicrobial stewardship programs; Bangladesh; children; COVID-19; guidelines; hospitals; outcomes

1. Introduction

The principal focus on children in low- and middle-income countries (LMICs) during the COVID-19 pandemic has been to address key issues, including the poor uptake of vaccinations and the envisaged impact as well as behavioural issues as a consequence of lockdowns and social distancing measures [1–6]. This resulted in Bangladesh organising immunisation outreach services for children and increasing the number of home visits to address concerns [3,7]. This is because children have a lower risk of infection with
COVID-19 than adults, with typically milder clinical manifestations [8–14] and an appreciable number are asymptomatic [11,15]. Cough, fever, diarrhoea, nausea and respiratory infections are generally the most frequent clinical characteristics of children with COVID-19, with boys typically more prone than girls [8,11–13,15,16]. Overall, it is estimated that approximately 6% to 10% of infected children experience severe disease, lower than rates seen in adults [11,12]. Consequently, the focus among children during the current pandemic has been on other infectious diseases and their prevention.

However, the focus on children is changing with new variants and their potential implications. In addition, whilst a lower percentage of children with severe symptoms are admitted to intensive care units (ICUs) in LMICs, deaths among the hospitalised children are higher [12].

There are also increasing concerns with the inappropriate use of antimicrobials across LMICs. Patients with COVID-19 in hospitals are typically administered antibiotics despite only a limited number having concomitant bacterial or fungal infections [17–22]. This includes hospitals in Bangladesh [23,24]. However, high inappropriate prescribing will increase antimicrobial resistance (AMR) rates, increasing morbidity, mortality and costs [25–32], with high rates of AMR already a concern in Bangladesh [33–36]. Children with COVID-19 can also develop Kawasaki Disease (KD)-like symptoms/hyperinflammatory syndromes [8,37–39] as well as experience leucopoenia with marked lymphopenia, hypotension, hypoalbuminemia, gastrointestinal and respiratory changes [37], potentially increasing ICU admissions.

There have also been concerns generally with the level of misinformation surrounding the management of COVID-19. This includes issues with hydroxychloroquine, lopinavir/ritonavir, remdesivir and ivermectin, with robust studies suggesting limited clinical benefit, although systematic reviews have suggested remdesivir can accelerate clinical improvement [40–49]. This is a concern as misinformation can increase morbidity, mortality and costs [50–53]. Concerns with misinformation have resulted in groups, including the World Health Organization (WHO) and the British Medical Journal (BMJ), providing evidence-based guidance [54–58]. International guidelines have also been developed to improve the management of children with COVID-19 in paediatric intensive care unit (PICU) countries [59]. The Ministry of Health and Family Welfare in Bangladesh also made national guidelines available from May 2020 onwards [60]. Similarly, the Bangladesh Paediatric Association has published its guidelines as this patient population is inherently a vulnerable one (Table 1) [61].

**Table 1.** Key recommendations for managing adults and children with COVID-19 in hospitals in Bangladesh (adapted from [60,61]).

| Treatment (General) |
|---------------------|
| - Moderate and severe cases should typically be treated in hospital, with more critical cases transferred to the ICU |
| - Monitoring of water and electrolyte balance as well as vital signs |
| - Oxygen saturation with oxygen therapy initiated if needed starting with low flow, including nasal catheter and mask oxygenation, before moving to high-flow oxygen therapy |

**Pharmacotherapy (moderate cases)***

| - Steroids—methylprednisolone injection |
| - Early norepinephrine for hypotension |
| - Broad-spectrum antibiotics, e.g., meropenam IV/based on local antibiograms |
| - Remdesivir—discretion of consultant working in the hospital. If favipiravir has already been started in patients with moderate disease, this should be stopped in favour of remdesivir |
| - Consider tocilizumab and convalescent plasma therapy for cytokine storm/hemophagocytic lymphohistiocytosis |

**Severe disease***

| - Additional oxygenation support for patients with severe disease |
| - If patients develop ARDS, intubation with mechanical ventilation will be needed; ECMO may be indicated in patients with refractory hypoxia in the ICU setting |
Table 1. Cont.

| Diagnosis and comorbidity |
|---------------------------|
| • Ideally, PCR test to confirm the diagnosis and subsequent management on a designated COVID-19 ward or treatment area |
| • Comorbid conditions can include bronchial asthma, chronic kidney or liver disease and rheumatological conditions, including Kawasaki disease |

| General treatment and ICU |
|---------------------------|
| • General treatment includes supportive care, electrolyte balancing and providing oxygen when necessary |
| • Children should be transferred to the paediatric ICU if they are experiencing severe/critical symptoms, respiratory failure requiring mechanical ventilation, shock, or organ failure. Treatment includes vasoactive drugs if required as well as balanced/buffered crystalloids |

| Children (November 2020) |
|---------------------------|
| Recommended medicines for treating children with COVID-19 |
| • Antivirals—potentially reserved for children with severe acute respiratory syndrome. If remdesivir, then ideally part of ongoing clinical trials. Conflicting evidence regarding lopinavir/ritonavir |
| • Antibiotics—specific cases only, avoiding excessive use. 1st line—ampicillin plus gentamicin; 2nd line—ceftriaxone |
| • Corticosteroids—not used routinely. Low-dose dexamethasone may be beneficial in children with severe disease |
| • Vitamins—may be beneficial |
| • For suspected Kawasaki Disease/MIS-C—typically admit to paediatric ICU with supportive care, including antibiotics for suspected infections as well as steroids and other immune modifying therapies |

ARDS—acute respiratory distress syndrome; ECMO—extracorporeal membrane oxygenation; ICU—Intensive Care Unit.

Consequently, we believe it is important to document the current management of children admitted to hospitals in Bangladesh with suspected or confirmed COVID-19, especially given concerns with antimicrobial use. In view of this, the objective of this study is to document current prevalence rates, treatments and outcomes of children with COVID-19, admitted to hospitals in Bangladesh in recent months. The findings can be used to suggest future quality improvement programmes in Bangladesh and other countries, if pertinent.

2. Results

We will first document the characteristics of patients admitted to hospitals across Bangladesh before documenting prescribed treatments and patient outcomes. One hundred and forty-six children were admitted with COVID-19 to the 24 hospitals taking part in this study, giving an overall prevalence of 3.7% (n = 3902, range = 0.55% to 29.5%) during the study period. COVID-19 was confirmed in the majority of admitted children by PCR tests (n = 111, 76%). The majority of admitted children were boys (n = 86, 58.9%) and were aged between 0 and 5 years (n = 91, 62.3%) (Table 2).

The consolidated principal reasons for hospital admission are documented in Table 3 based on pre-determined choices (Methodology Section 4.2), with only a limited number of children (n = 20, 13.7% including one referral) transferred to the PICU, typically with low oxygen saturation (Table 3, Figure 1). Children were typically admitted with more than one symptom, with Table 3 documenting the consolidated principal reasons for admission among participating hospitals. Potential reasons for admission to the PICU were also pre-determined and are documented in the Methodology Section 4.2. There were only a limited number of comorbidities among admitted children with COVID-19. These included bronchial asthma, dilated cardiomyopathy, congenital heart disease, dengue, nephrotic syndrome, malnutrition, pneumonia, sepsis and urinary tract infections.
Table 2. Patient characteristics among the 24 participating hospitals during the study period.

| Hospital | Date Survey Conducted | Total Number of Admitted Children during the Study Period | Total Number of Children with COVID-19 (No.) | % of Admitted Children with COVID-19 | Number of Children with Confirmed COVID-19 (No. and %) | Number of Boys (No.) | Number of Girls (No.) | 0 to 5 Years of Age (No.) | 6 to 10 Years of Age (No.) | 11 to 18 Years of Age (No.) | 2022, 11, x FOR PEER REVIEW 5 of 18 |
|----------|-----------------------|--------------------------------------------------------|------------------------------------------|--------------------------------|---------------------------------------------------|-------------------|-------------------|----------------------|-----------------------|------------------------|----------------------|
| 1—Priv   | 20 July 2021          | 14                                                     | 2                                        | 14.3%                             | 2 (100%)                                          | 0                 | 2                 | 1                     | 0                     | 0                      | 1                    |
| 2—Priv   | 29 July 2021          | 18                                                     | 1                                        | 5.6%                              | 1 (100%)                                          | 1                 | 0                 | 0                     | 0                     | 1                      | 0                    |
| 3—Priv   | 30 July 2021          | 19                                                     | 2                                        | 10.5%                             | 1 (one susp.)                                     | 1                 | 1                 | 1                     | 1                     | 1                      | 1                    |
| 4—Priv   | 16 July 2021          | 32                                                     | 2                                        | 6.3%                              | 0 (2 susp.)                                       | 1                 | 1                 | 2                     | 0                     | 0                      | 0                    |
| 5—Priv   | 31 August 2021        | 40                                                     | 5                                        | 12.5%                             | 5 (100%)                                          | 2                 | 3                 | 2                     | 2                     | 2                      | 1                    |
| 6—Priv   | 30 July 2021          | 41                                                     | 3                                        | 7.3%                              | 3 (100%)                                          | 3                 | 0                 | 2                     | 0                     | 1                      | 1                    |
| 7—Pub    | 04 February 2021      | 44                                                     | 13                                       | 29.9%                             | 1 (12 susp.)                                      | 5                 | 8                 | 11                    | 2                     | 0                      | 0                    |
| 8—Priv   | 11 July 2021          | 50                                                     | 5                                        | 10.0%                             | 0 (5 susp.)                                       | 4                 | 11                | 3                     | 2                     | 0                      | 0                    |
| 9—Priv   | 24 July 2021          | 61                                                     | 5                                        | 8.2%                              | 5 (100%)                                          | 3                 | 2                 | 1                     | 2                     | 2                      | 2                    |
| 10—Priv  | 11 August 2021        | 65                                                     | 3                                        | 4.6%                              | 3 (100%)                                          | 2                 | 1                 | 3                     | 0                     | 0                      | 0                    |
| 11—Priv  | 01 August 2021        | 66                                                     | 6                                        | 8.8%                              | 6 (100%)                                          | 5                 | 1                 | 3                     | 3                     | 3                      | 3                    |
| 12—Priv  | 30 July 21            | 75                                                     | 15                                       | 20.0%                             | 15 (100%)                                         | 9                 | 6                 | 4                     | 9                     | 2                      | 2                    |
| 13—Priv  | 30 August 2021        | 85                                                     | 4                                        | 4.7%                              | 4 (100%)                                          | 2                 | 2                 | 3                     | 1                     | 0                      | 0                    |
| 14—Priv  | 04 August 2021        | 103                                                    | 24                                       | 18.6%                             | 0 (14 susp.)                                      | 10                | 4                 | 13                    | 0                     | 1                      | 1                    |
| 15—Pub   | 30 July 2021          | 105                                                    | 1                                        | 1.0%                              | 1 (100%)                                          | 1                 | 0                 | 1                     | 0                     | 0                      | 0                    |
| 16—Pub   | 31 August 2021        | 125                                                    | 5                                        | 4.0%                              | 5 (100%)                                          | 4                 | 1                 | 2                     | 3                     | 3                      | 3                    |
| 17—Pub   | 04 August 2021        | 68                                                     | 3                                        | 4.4%                              | 3 (100%)                                          | 2                 | 1                 | 2                     | 0                     | 1                      | 1                    |
| 18—Pub   | 31 July 2021          | 210                                                    | 26                                       | 12.4%                             | 26 (100%)                                         | 15                | 11                | 13                    | 6                     | 7                      | 7                    |
| 19—Pub   | 11 July 2021          | 296                                                    | 3                                        | 1.2%                              | 3 (100%)                                          | 2                 | 1                 | 2                     | 1                     | 1                      | 1                    |
| 20—Pub   | 08 October 2021       | 362                                                    | 3                                        | 0.83%                             | 3 (100%)                                          | 1                 | 2                 | 0                     | 0                     | 3                      | 3                    |
| 21—Pub   | 11 July 2021          | 382                                                    | 3                                        | 0.8%                              | 0 (1 susp.)                                       | 2                 | 1                 | 3                     | 0                     | 0                      | 0                    |
| 22—Pub   | 08 November 2021      | 583                                                    | 8                                        | 1.4%                              | 8 (100%)                                          | 5                 | 3                 | 6                     | 1                     | 1                      | 1                    |
| 23—Pub   | 08 November 2021      | 442                                                    | 5                                        | 1.1%                              | 5 (100%)                                          | 1                 | 4                 | 4                     | 1                     | 0                      | 0                    |
| 24—Pub   | 17 July 2021          | 654                                                    | 9                                        | 1.4%                              | 9 (100%)                                          | 5                 | 4                 | 9                     | 0                     | 0                      | 0                    |

Column 3 includes children admitted during the study period and not on any specific day; Priv = private (including not for profit) hospital; Pub = public hospital; Confirmed—by PCR testing; susp = suspected.

Table 4 contains the consolidated list of antibiotics (class or specific) prescribed for children with suspected or confirmed COVID-19 among the participating hospitals. As seen, there was a considerable prescribing of antibiotics, with 86.3% (126/146) of children prescribed them, with almost all antibiotics administered empirically (98.4%—124/126). In general, antibiotics were prescribed from the WHO Watch list as opposed to the Reserve list. In addition, antibiotics were typically administered parenterally with generally limited

Figure 1. Reasons for hospital admission of children with COVID-19 (n = 146).

Table 4 contains the consolidated list of antibiotics (class or specific) prescribed for children with suspected or confirmed COVID-19 among the participating hospitals. As seen, there was a considerable prescribing of antibiotics, with 86.3% (126/146) of children prescribed them, with almost all antibiotics administered empirically (98.4%—124/126). In general, antibiotics were prescribed from the WHO Watch list as opposed to the Reserve list. In addition, antibiotics were typically administered parenterally with generally limited
prescribing of oral antibiotics, including switching, for between 3 and 14 days. Children were generally assessed after 2 to 3 days (Table 4).

Table 3. Rationale for admission to the hospital and those subsequently admitted to the PICU.

| Hospital   | Principal Documented Reasons for Hospital Admission for Children with Suspected COVID-19 during the Study Period | Total Number of Children Subsequently Admitted with COVID-19 to PICUs | Principal Reasons for PICU Admission |
|------------|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------|
| 1—Priv     | Respiratory distress                                                                                   | 2                                                                   | Low oxygen saturation, comorbidities |
| 2—Priv     | Fever, coughing, vomiting                                                                             | 0                                                                   | Not applicable                       |
| 3—Priv     | Fever, cough, low SPO2, respiratory distress, vomiting, diarrhoea                                     | 0                                                                   | Not applicable                       |
| 4—Priv     | Fever, cough, respiratory distress                                                                  | 0                                                                   | Not applicable                       |
| 5—Priv     | Prolonged fever, respiratory distress, diarrhoea                                                      | 1                                                                   | Low oxygen saturation, extensive involvement in high-resolution CT scan |
| 6—Priv     | Prolonged fever, cough, respiratory distress                                                          | 0                                                                   | Not applicable                       |
| 7—Pub      | Fever, cough, respiratory distress                                                                  | 0 (1 referred) *                                                    | Unexplained bleeding                 |
| 8—Priv     | Prolonged fever, breathing difficulties, diarrhoea                                                     | 1                                                                   | Shock                                |
| 9—Priv     | Fever, cough, feeding difficulties                                                                    | 1                                                                   | Shock, myocarditis                   |
| 10—Priv    | Respiratory distress, cough, feeding difficulties                                                     | 0                                                                   | Not applicable                       |
| 11—Priv    | Fever, cough, feeding difficulties                                                                    | 2                                                                   | Low oxygen saturation, respiratory distress, shock |
| 12—Priv    | Fever, respiratory distress, feeding difficulty                                                       | 0                                                                   | Not applicable                       |
| 13—Priv    | Prolonged fever, cough, breathing difficulty/respiratory distress                                     | 0                                                                   | Not applicable                       |
| 14—Priv    | Fever, respiratory distress, feeding difficulty                                                       | 0                                                                   | Not applicable                       |
| 15—Pub     | Fever, cough, respiratory distress                                                                   | 0                                                                   | Not applicable                       |
| 16—Pub     | Prolonged fever, cough, Breathing difficulties/respiratory distress, diarrhoea                         | 0                                                                   | Not applicable                       |
| 17—Pub     | Fever, cough, respiratory distress                                                                    | 0                                                                   | Not applicable                       |
| 18—Pub     | Fever, cough, low SPO2, respiratory distress, vomiting                                               | 9                                                                   | Fever, shock, low oxygen saturation, vomiting, feeding difficulties |
| 19—Pub     | Fever, cough, respiratory distress                                                                   | 0                                                                   | Not applicable                       |
| 20—Pub     | Fever, cough, respiratory distress                                                                    | 1                                                                   | Low oxygen saturation and comorbidities |
| 21—Pub     | Prolonged fever, cough, respiratory distress                                                          | 0                                                                   | Not applicable                       |
| 22—Pub     | Fever, cough, respiratory distress                                                                    | 2                                                                   | Perinatal asphyxia, feeding difficulty, low oxygen saturation       |
| 23—Pub     | Fever, cough, respiratory distress                                                                    | 0                                                                   | Not applicable                       |
| 24—Pub     | Prolonged fever, respiratory distress, feeding difficulties                                           | 0                                                                   | Not applicable                       |

PICU = Paediatric Intensive Care Unit; Priv = private hospital; Pub = public hospital; SPO2 = Saturation of peripheral oxygen; * referred to the PICU in another hospital.
Table 4. Clinical management of children with COVID-19 among the 24 hospitals.

| Hospital | Number and % Prescribed Antibiotics | Empiric or Following CST | Principal Antibiotics Prescribed (Actual or Class) for Children with COVID-19 | Antiviral Medicines Prescribed | Antiparasitic Medicines Prescribed | Duration of Antibiotic Prescribing (Days) | Clinical Assessment of Antibiotics (Days after Start of Treatment) |
|----------|-------------------------------------|--------------------------|--------------------------------------------------------------------------|--------------------------------|-----------------------------------|--------------------------------------|------------------------------------------------------------|
| 1—Priv   | 2 (100%)                            | All Empiric              | Carbapenem, cephalosporins                                              | No                             | No                                | 4–7                                  | 3                                                          |
| 2—Priv   | 1 (100%)                            | All Empiric              | Ceftriaxone                                                              | No                             | No                                | 5                                    | 5                                                          |
| 3—Priv   | 2 (100%)                            | All Empiric              | Ceftriaxone, ciprofloxacin                                               | No                             | No                                | 3 and 5                               | 3–5                                                       |
| 4—Priv   | 2 (100%)                            | All Empiric              | Ampicillin, aminoglycosides, cephalosporins                              | No                             | No                                | 5                                    | 2                                                          |
| 5—Priv   | 5 (100%)                            | All Empiric              | Cephalosporins, quinolones                                               | Remdesivir (2 patients)        | No                                | 7                                    | 2                                                          |
| 6—Priv   | 2 (66.7%)                           | All Empiric              | Cephalosporins                                                          | No                             | No                                | 5–7                                  | 5–7                                                       |
| 7—Pub    | 13 (100%)                           | All Empiric              | Ceftriaxone, amikacin, meropenem                                         | No                             | No                                | 5–7                                  | 3                                                          |
| 8—Priv   | 5 (100%)                            | All Empiric              | Carbapenem, aminoglycosides, cephalosporins                              | No                             | No                                | 5–7                                  | 3                                                          |
| 9—Priv   | 2 (40%)                             | All Empiric              | Vancomycin, meropenem, cloximeclav                                       | Remdesivir (1 patient)         | No                                | 7–10                                 | 3                                                          |
| 10—Priv  | 3 (100%)                            | All Empiric              | Ceftriaxone                                                              | No                             | No                                | 10                                   | 3                                                          |
| 11—Priv  | 4 (66.7%)                           | All Empiric              | Ceftriaxone, ciprofloxacin, amikacin                                     | Remdesivir (1 patient)         | No                                | 3–7                                  | 3                                                          |
| 12—Priv  | 2 (13.3%)                           | 1 Empiric/1 CST          | Aminoglycosides, cephalosporins, quinolones                              | No                             | No                                | 5–7                                  | Not recorded                                               |
| 13—Priv  | 4 (100%)                            | All Empiric              | Aminoglycosides, cephalosporins                                          | No                             | Ivermectin (1 patient)            | 10                                   | 3–5                                                       |
| 14—Priv  | 14 (100%)                           | All Empiric              | Aminoglycosides, penicillin, cephalosporins                              | No                             | No                                | 5–7                                  | 3                                                          |
| 15—Pub   | 1 (100%)                            | All Empiric              | Cefixime                                                                 | No                             | No                                | 7                                    | 3                                                          |
| 16—Pub   | 5 (100%)                            | All Empiric              | Aminoglycosides, carbapenem, cephalosporins                              | No                             | No                                | 7–10                                 | 2–3                                                       |
| 17—Pub   | 3 (100%)                            | All Empiric              | Ceftriaxone, ceftazidim, gentamicin                                      | No                             | No                                | 3–7                                  | 3                                                          |
| 18—Pub   | 26 (100%)                           | All Empiric              | Ceftriaxone, ceftazidim, meropenem, vancomycin, flucloxacin, amikacin    | No                             | No                                | 5–11                                 | 5–10                                                      |
| 19—Pub   | 3 (100%)                            | All Empiric              | Ceftriaxone, meropenem                                                   | No                             | No                                | 7                                    | 3                                                          |
| 20—Pub   | 3 (100%)                            | All Empiric              | Penicillin, carbapenem, aminoglycosides                                  | Remdesivir (3 patients), acyclovir (1 patient) | No | 8–14 | 3 |
| 21—Pub   | 3 (100%)                            | All Empiric              | Amikacin, meropenem                                                      | No                             | No                                | 7                                    | 2                                                          |
| 22—Pub   | 7 (87.5%)                           | 6 Empiric/1 CST          | Ceftriaxone, amikacin, meropenem                                         | No                             | No                                | 4–7                                  | 3                                                          |
| 23—Pub   | 5 (100%)                            | All Empiric              | Ceftriaxone, amikacin, meropenem                                         | No                             | No                                | 7–14                                 | 3                                                          |
| 24—Pub   | 9 (100%)                            | All Empiric              | Aminoglycosides, carbapenem, macrolides                                  | No                             | No                                | 7 days (minimum)                      | 3                                                          |
| Total    | 126 children—(86.3%)               |                          | 124 empiric (96.4%)                                                     | 8 children (5.5%)              | 1 child (0.7%)                    |                                       |                                                            |

Antibiotics could also be prescribed for underlying comorbidities; Priv = private (including not for profit) hospital; Pub = public hospital.
There was no prescribing of hydroxychloroquine for any child admitted with COVID-19 in the surveyed hospitals and very limited prescribing of either antivirals, including remdesivir, or antiparasitic medicines, including ivermectin (Table 4). Steroids were prescribed to children in 13 of the surveyed hospitals (n = 13, 54.2%), with immune boosters, including vitamins C and D, prescribed to children in 14 of the participating hospitals (n = 14, 58.3% of hospitals).

There were lower rates of prescribing of antibiotics among those hospitals where the clinicians stated that they had followed the Bangladesh Paediatric Association guidelines (Tables 1 and 5). However, there was no significant statistical association (p = 0.127) between the administration of antibiotics and the clinicians in the participating hospitals who had stated they had complied with the Paediatric Association guidelines when prescribing antibiotics to children with suspected or confirmed COVID-19 and those who had not (Table 5).

Table 5. Prescribing of antibiotics and adherence to Bangladesh Paediatric Association guidelines.

| Guideline adherence | Number of Children Administered Antibiotics | Number of Children Not Administered Antibiotics | % Administered Antibiotics |
|---------------------|---------------------------------------------|-----------------------------------------------|----------------------------|
| Hospitals where clinicians stated that they had followed the Paediatric Association guidelines | 74                                           | 15                                            | 83.1% (n = 89)             |
| Hospitals where clinicians stated that they had not followed the Paediatric Association guidelines | 52                                           | 5                                             | 91.2% (n = 57)             |

Total number of children = 146.

Encouragingly, at 1.4% (2/146), there were only a limited number of deaths among the children admitted with COVID-19, with 92.5% making a full recovery (135/146). The remainder still had complications during the study period.

3. Discussion

To the best of our knowledge, this is the first comprehensive study conducted among a range of both private and public hospitals across Bangladesh concerning the management of children hospitalised with suspected or confirmed COVID-19. Our findings build on the earlier study of Hussain et al. (2020), who found a higher mortality rate (13.3%) among children during the early stages of the pandemic [3], and the recent pilot studies conducted among children in Bangladesh and India [62,63]. The reduced mortality among children hospitalised with COVID-19 in our study (1.4%) compared with the study conducted by Hussain et al. (2020) may reflect improved clinical management as more knowledge is gained regarding the aetiology of COVID-19, especially with greater recognition of Kawasaki disease (KD)-like symptoms/hyperinflammatory syndromes among these children [8,37–39]. In addition, greater knowledge of treatment approaches has resulted in the development of updated guidelines (Table 1) as well as updated advice from groups such as the WHO and the BMJ [54,58]. However, further research is needed on this topic before we can say anything with certainty. Having said this, only a low number of children were admitted to these general hospitals in Bangladesh with COVID-19 (Table 2), similar to the findings of other recent publications, including the recent pilot study in India [11,13,15,63].

Fever, cough and respiratory diseases were, again, the most frequent clinical characteristics of children admitted to the surveyed hospitals with COVID-19 (Table 3, Figure 1), with admission to hospital with suspected or confirmed COVID-19 also more common among boys (58.9%), similar to other studies [8,11–13,15,16,63].

Encouragingly there was limited prescribing of antiviral, antiparasitic and antimalarial medicines among the children with COVID-19 admitted to the surveyed hospitals (Table 4). This is in line with recommendations in the Bangladesh Paediatric guidelines (Table 1), with similar guidance in other countries [61,64,65]. This is important given concerns with the lack of effectiveness of these medicines in treating patients with COVID-19, despite the initial
hype [40,41,43,44]. Encouragingly, the prescribing of immunomodulators such as vitamins and zinc also appeared to be in line with the paediatric guidelines (Table 1). However, we are beginning to see immunomodulators being discouraged in some LMICs [65].

However, there were concerns with the high empiric use of antibiotics among the children in the surveyed hospitals (Table 3), which is similar to their high use among adults admitted to hospitals with COVID-19 in Bangladesh [23,24]. These rates (86.3%) are higher than a recent pilot study undertaken in India, with rates of 69.4% [63]. This is despite, as mentioned, only a limited number of patients with COVID-19 across ages having concomitant bacterial or fungal infections [17–22,31,66]. In addition, the Paediatric Association guidelines advocate only the prudent use of antibiotics due to concerns with potential over-use (Table 1). However, the rates of antibiotic prescribing appear to be less among children where the clinicians have stated they followed paediatric guidelines (Table 5); however, this was not statistically significant. In any event, these high rates need to be addressed, going forward, to reduce future AMR.

Potential ways forward to improve the rational use of antibiotics among these children include instigating antimicrobial stewardship programmes (ASPs), combined with an additional COVID-19 module, and other educational activities; these currently do not exist. Such activities have been successful across LMICs to improve the rational use of antibiotics in a number of situations [28,29,32,36,67–72].

Future activities should also include encouraging antibiotic prescribing according to local antibiograms where initial prescribing is typically empiric, combined with instigating ASPs [35,73–75]. These combined activities should help reduce the extent of prescribing ‘Watch’ antibiotics in favour of the increased prescribing of ‘Access’ antibiotics, where pertinent (Tables 2 and 4) [76,77]. ASPs could also potentially encourage earlier switching from parental to oral antibiotics where it is pertinent and practical to hasten earlier discharge and conserve resources [78–80]. This is important with the current practice of limited switching to oral antibiotics among the surveyed hospitals. We will be following up on these identified issues in future studies to improve antibiotic prescribing in Bangladesh, given continual concerns with high rates of AMR [33–35,81].

The seemingly low number of children admitted to these general hospitals in Bangladesh versus other conditions is important when considering future priorities with limited resources. This includes reviewing the clinical conditions of the other admitted children during this period without COVID-19 and whether resources should be focused on these children instead. In addition, there are key areas such as vaccinations to prevent future infections among children [28]. We are aware that in Bangladesh and other LMICs, vaccination rates have been appreciably compromised by lockdowns and other measures [1–5]. Whilst this was not a focus for this study, we are aware that the direct and indirect impact of COVID-19 on children has been underestimated. Children in LMICs are more likely to suffer from other comorbidities such as other respiratory tract infections, including pneumonia as well as malnutrition and HIV, which may complicate a COVID 19 diagnosis [82]. Consequently, we will also be following up on these issues as well in future research projects to provide additional guidance to all key stakeholder groups in Bangladesh and other countries.

We are aware of several limitations with this study. These included the fact that this was only a retrospective review of medical records without the ability to check with physicians regarding the rationale for any prescribing, especially of antibiotics. We were also limited by the extent of information that could be collected from the surveyed hospitals, and all cases of COVID-19 could not be confirmed by rt-PCR. We also could not analyse any differences between private and public hospitals as admission and other key criteria were not standardised. In addition, we extended the study period in each hospital in order to collect more data on the management of children with COVID-19. Consequently, our prevalence rates of admitted children could be overestimated. However, despite these limitations, we believe our findings are robust, given the number of participating hospitals, providing direction for future quality improvement programmes and other activities.
4. Materials and Methods

4.1. Study Setting and Design

The study was undertaken among a range of hospitals \( (n = 24) \) across Bangladesh, admitting children with suspected or confirmed COVID-19. Both private and public hospitals were included to ensure full representation, similar to point prevalence surveys conducted in other healthcare systems with a mixture of hospital types [83–85]. Initially, children in Bangladesh with COVID-19 were referred to public hospitals, mainly medical college hospitals. However, this changed, with private hospitals subsequently able to treat children admitted with COVID-19.

Private and public hospitals were not analysed separately due to anticipated different admission criteria, making comparisons problematic and difficult to justify. In addition, the aims of the study were to gain insights into current prevalence rates among children admitted with suspected COVID-19 to hospitals in Bangladesh, as well as insights into current management practices, rather than to assess differences in treatments and outcomes between different hospital types. This included the current prescribing of antimicrobials among hospitals in Bangladesh. The hospitals were purposely selected based on their ability to provide pertinent data as well as maximum variation in terms of their geography, location and size (Table 2).

This point prevalence survey was conducted based on standardised methodologies, with the data forms adapted to meet the specific requirements of the study and setting [62,83–88] (Supplementary Material File S1). Data were gathered from the medical records of children admitted to hospital with suspected or confirmed COVID-19 between July and November 2021. This included children subsequently admitted to PICUs, if such facilities existed in the hospital. Care in public hospitals in Bangladesh for these patients is typically provided without the need for co-payments. However, there are charges for patients admitted to private hospitals.

4.2. The Data Collection Tool and Analysis

A paper-based data collection tool was used by the investigators to collect the necessary information at the patient level. The specific forms were adapted from previous point prevalence surveys conducted in LMICs involving a number of co-authors [83,85–92]. This was combined with a synthesis of current guidelines for managing children with COVID-19 in Bangladesh (Table 1), a synthesis of the current literature [3,11,12,20,93] and a cognisance of the study aims and objectives. The data collection forms were pre-tested to ensure they would meet the study objectives. A pilot study was undertaken among a limited number of hospitals in Bangladesh [62] prior to full roll-out, with a similar pilot study undertaken in India [63]. The same forms were subsequently used in this multicentre study in Bangladesh as they were able to provide the relevant information to meet the aims and objectives of the study (Supplementary Material File S1).

There were no exclusion criteria. All children admitted on the day of data collection and during the previous nine days were included to give a combined total over a ten-day period.

The key data sets collected and the rationale for their inclusion in the data collection forms, where pertinent, are included in Table 6. The information was collected by the principal investigator in each hospital, with initial data collection taking place on one specific day, similar to other PPS studies. The medical records of patients admitted in the previous ten days were also viewed. Ten days were chosen for this study by the principal investigators because of the anticipated low numbers of children with COVID-19 actually admitted to general hospitals in Bangladesh on any specific day, with children with COVID-19 generally asymptomatic or with milder clinical manifestations versus adults [8,10–13]. Alongside this, there were anticipated low numbers of children with COVID-19 in the participating hospitals compared with other conditions of admitted children. In addition, as mentioned, the principal objective of the study was to gain knowledge of current management practices, including any concerns with antimicrobial
use, rather than a robust assessment of prevalence rates. Children were also followed up, if necessary, to determine the average number of days they were prescribed antibiotics and when re-assessed.

**Table 6.** Key data sets collected and their rationale.

| Key Data Sets | Rationale |
|---------------|-----------|
| Number of paediatric patients being treated in the hospital during the ten-day period and the number with COVID-19 | To gain insight into current prevalence rates among children admitted to hospitals in Bangladesh compared with other conditions |
| Whether COVID-19 was suspected or confirmed—confirmed with PCR tests | To gain additional insight into current COVID-diagnostic practices |
| The ages of admitted children | Patients’ ages were broken down into 3 bands: 0–5 years; 6–10 years; 11–18 years for comparative purposes based on the pilot study in both Bangladesh and India [62,63] |
| Principal reason for admission to hospital with actual/suspected COVID-19 | • Potentially up to 3 principal reasons for admission could be recorded among participating hospitals
• These were taken from a drop-down menu in the Microsoft Excel® spreadsheets and consisted of (i) breathing difficulties/respiratory distress; (ii) prolonged fever; (iii) cough; (iv) diarrhoea; and (v) feeding difficulty/vomiting
• These reasons were taken from the current literature, combined with input from paediatricians in Bangladesh, and tested in the pilot study [8,9,11–13,62]
• Consolidating the reasons would assist with analysis and comparisons with published studies |
| Comorbidities | Based on evidence amongst adults that certain comorbidities do have an impact on morbidity and mortality associated with COVID-19 [94,95] |
| Number of children admitted to PICU and the rationale | • The potential reasons for admittance taken from the literature and input from paediatricians in Bangladesh included: (i) severe respiratory distress/low O₂ saturation; (ii) shock; (iii) coagulation disorders/thromboembolic manifestations; and (iv) extensive lung involvement in high-resolution CT scans (HRCTs) [9,13,62]
• These potential reasons were standardised in the data collection forms for ease of recording and analysis and tested in the pilot study |
| Number of children prescribed antibiotics and the antibiotics prescribed (by ATC Level 4 Grouping or individual antibiotics), and whether empiric or following CST findings | • This was assessed given concerns with potential over-prescribing coupled with guidance from the Bangladesh Paediatric Association, advocating prudence [61]
• Antibiotic prescribing also assessed against the WHO Access, Watch, or Reserve (AwaRe) list, given the increasing importance of this list to guide future antimicrobial policies and practices [76,86,88,96,97]
• The list of antibiotics prescribed for admitted children in specific hospitals was provided in a menu in the Case Report Forms (Supplementary Material File S1) and consolidated for tabulation and analysis |
| Route of administration, whether the rationale for antibiotic prescribing was re-assessed, and, if so, after how many days, and total length of antibiotic prescriptions | • Given prior awareness that antibiotics administered to children admitted to hospital are usually administered by IV
• To determine whether:
  ○ There was any scaling down to oral antibiotics, as this can shorten hospital length of stay [91,98,99]. If so, the extent
  ○ There was any documented rationale for the antibiotics prescribed when re-assessed, especially with high empiric use, to help guide future quality improvement programmes among hospitals in Bangladesh |
Table 6. Cont.

| Key Data Sets                                                                 | Rationale                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The extent of prescribing of antivirals, e.g., remdesivir, antimalarials, e.g., hydroxychloroquine, and antiparasitic medicines, e.g., ivermectin | • Assessed, given concerns with their effectiveness and safety as more robust data became available, and should be reserved if administered (antivirals) according to the Bangladesh Paediatric Guidelines [40,43,44,46,48,61]  
• Potentially, remdesivir for the management of patients in hospital with moderate to severe COVID-19 requiring oxygen, in the national Ministry of Health guidelines issued in Spring 2020 [60]—discretion of the hospital consultant |
| The extent of prescribing of dexamethasone and other steroids, including methylprednisolone | Seen as potentially beneficial, especially among hospitalised patients, and endorsed in the guidelines [46,61,100]                                                                                                                                                                                                                     |
| Use of supplements/immune boosters including vitamins C or D or zinc           | Discussed in the Bangladesh Paediatric Guidelines, with publications suggesting potential benefit [61,101,102]                                                                                                                                                                                                                     |
| Adherence to current guidelines, including those developed by the Bangladesh Paediatric Association —Table 1 [50] | • Adherence to robust guidelines is increasingly recognised as a key marker of quality used in the Global PPS studies as well as across hospitals in LMICs [83,103–105], given the concerns that can exist among LMICs [106–108]  
• Published studies have shown that adherence to guidelines improves antimicrobial prescribing, as seen with the management of surgical site infections across LMICs as well as with the monitoring of prescribing guidance, built into antimicrobial stewardship programmes [28,67,70,109]  
• However, adherence is not monitored and potentially enforced as the Bangladesh Paediatric Association is a non-government organisation. This is different to the situation that can exist across countries, sectors and disease areas [28,110,111] |
| Outcome—fully recovered, morbidity or mortality                               | • Pertinent study endpoints  
• Taken from the medical records of children during the study period by the principal investigator in each hospital                                                                                                                                                                                                                   |
| Possible costs (principally private hospitals) (based on local currency)       | • These were based on possible charges by the hospital (typically private hospitals)  
• No attempt was made to undertake costing studies in public hospitals as this was not the objective of the paper                                                                                                                                                                                                                   |

PICU = Pediatric Intensive Care Unit.

Data were collated by the principal investigator in each participating hospital and subsequently entered into Microsoft Excel® spreadsheets for analysis. As mentioned (Table 6), these contained drop-down menus with options for specific questions. The aggregated data for each hospital was subsequently transferred to the principal investigator collating the findings (BG) for analysis, with the ability to re-check and re-validate data when the need arose with the co-authors from the pertinent hospitals.

Descriptive statistics were typically used to summarise and collate the data using proportions (%) as appropriate, given the likely differences in admittance criteria between hospitals. However, the chi-square statistical test was used to assess whether there were significant differences in antibiotic prescribing between those hospitals that stipulated they followed current guidelines versus the remainder, with a p-value < 0.05 seen as significant (Table 5).

4.3. Patient and Hospital Anonymity and Ethical Approval

Patient anonymity was maintained throughout the study by the principal investigator in each hospital. Only aggregated anonymised data for each hospital was forwarded to the principal investigator collating the findings (BG) for analysis. Additionally, in the final
analysis, hospitals were assigned a study identification number rather than each hospital being specifically identified (Hospitals 1 to 24).

Parents or guardians were not approached for consent since this was a retrospective study based on data collated from patients' medical records, with no direct contact with children, their parents, or guardians. This is in line with previous point prevalence surveys undertaken by the co-authors [84,86,88–90,92,112].

The principal investigators orchestrated ethical approval for the hospitals and others involved in the study. The reference numbers are ibh/mirpur/2020/01; GSVMC/2021/346; BBEC, JU/M 2021/COVID-19/7 and AWMC/IRB-21 July 2021/028.

5. Conclusions

The low rates for the hospitalisation of children with COVID-19 among the surveyed hospitals in Bangladesh are encouraging and mirror the findings in other countries.

It was also encouraging to see limited prescribing of repurposed antimicrobials, including antimalarials, antivirals and antiparasitic medicines, given the hype that has surrounded these treatments, particularly hydroxychloroquine, which were without foundation once the findings from robust studies, including the WHO Solidarity and the UK Recovery studies, became known. This is important for promoting evidence-based approaches in the future.

However, high rates of the prescribing of antibiotics, often empiric, even among hospitals stating they are following the Paediatric Association guidelines, coupled with limited switching to oral formulations, are a concern. These issues need to be urgently addressed in Bangladesh, going forward, given the already high rates of AMR in the country coupled with ongoing resource pressures. This is important to reduce future morbidity, mortality, and costs. The instigation of local antibiograms and ASPs are key ways forward to improve future antibiotic use in hospitals in Bangladesh as well as LMICs generally. We will be monitoring such activities in the future.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/antibiotics11010105/s1, File S1: Bangladesh: COVID-19 Pediatric Case Management.

Author Contributions: Conception/design: K.C., M.H. (Mainul Haque), N.N. (Nadia Nusrat), N.A. (Nihad Adnan), N.S. (Natalie Schellack), A.K., M.G., J.C.M., S.O., B.G. Acquisition and analysis: K.C., M.H. (Mainul Haque), N.N. (Nadia Nusrat), N.A. (Nihad Adnan), S.I., A.B.L., D.B., A.R., E.K., A.M., N.J., J.A., S.A. (Sumala Ashraf), M.N.H., M.H. (Mahmuda Hassan), N.A. (Najnin Akhter), M.M., N.S. (Nazmus Sihan), N.N. (Nurun Naher), S.A. (Shaheen Akter), S.U.Z., T.C., J.N., S.B., M.D.I., A.M.H., H.R., P.K.B., M.S., F.C., A.K., N.S. (Natalie Schellack), J.C.M., B.G. Interpretation of the data: K.C., M.H. (Mainul Haque), N.N., N.A. (Nihad Adnan), S.I., A.B.L., S.K., A.K., Z.U.M., N.S. (Natalie Schellack), M.G., J.C.M., S.O., B.G. Drafting the work: K.C., M.H. (Mainul Haque), N.N. (Nadia Nusrat), S.K., A.K., N.S. (Natalie Schellack), M.G., J.C.M., S.O., B.G. Critically revising the paper: all authors. Accuracy of the data appropriately collected and included in the analysis as well as resolving queries: K.C., M.H. (Mainul Haque), N.N. (Nadia Nusrat), N.A. (Nihad Adnan), S.I., A.B.L., D.B., A.R., E.K., A.M., N.J., J.A., S.A. (Sumala Ashraf), M.N.H., M.H. (Mahmuda Hassan), N.A. (Najnin Akhter), M.M., N.S. (Nazmus Sihan), N.N. (Nurun Naher), S.A. (Shaheen Akter), S.U.Z., T.C., J.N., S.B., M.D.I., A.M.H., H.R., P.K.B., M.S., F.C., A.K., N.S. (Natalie Schellack), J.C.M., B.G. All authors have read and agreed to the published version of the manuscript.

Funding: There was no funding for this paper. The data collection and the development of the paper was funded by the co-authors.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. The principal investigators orchestrated ethical approval for the hospitals and others involved in the study. The reference numbers are ibh/mirpur/2020/01, date: 31 August 2021; GSVMC/2021/346, date: 22 August 2021; BBEC, JU/M 2021/COVID-19/7, date: 18 July 2021, DLMCH/IEC2021/1, date: 06 October 2021, and AWMC/IRB-21 July 2021/028, date: 10 August 2021.

Informed Consent Statement: As mentioned, parents or guardians were not approached for consent since this was a retrospective study based on data collated from patients' medical records, with no
direct contact with children, their parents, or guardians. This is in line with previous point prevalence studies undertaken by the co-authors [84,86,88–90,92,112].

**Data Availability Statement:** Further data regarding the study is available upon reasonable request.

**Acknowledgments:** The authors would like to thank Niam Chy from the University of Chittagong, Bangladesh, for his help with producing the figures.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Abbas, K.; Procter, S.R.; van Zandvoort, K.; Clark, A.; Funk, S.; Mengistu, T.; Hogan, D.; Dansereau, E.; Jit, M.; Flasche, S.; et al. Routine childhood immunisation during the COVID-19 pandemic in Africa: A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. *Lancet Glob. Health*. 2020, 8, e1264–e1272. [CrossRef]

2. Gaythorpe, K.A.; Abbas, K.; Huber, J.; Karachaliou, A.; Thakkar, N.; Woodruff, K.; Li, X.; Echeverria-Londono, S.; Fouda, A.A.B.; Cutts, F.; et al. Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. *eLife* 2021, 10, e67023. [CrossRef] [PubMed]

3. Hussain, M.; Al Mamun, M.A. COVID-19 in children in Bangladesh: Situation analysis. *Asia Pac. J. Paediatr. Child Health* 2020, 3, 59–65.

4. Lassi, Z.; Naseem, R.; Salam, R.; Siddiqui, F.; Das, J. The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review. *Int. J. Environ. Res. Public Health* 2021, 18, 988. [CrossRef] [PubMed]

5. Sama, B.K.; Kaur, P.; Thind, P.S.; Verma, M.K.; Kaur, M.; Singh, D.D. Implications of COVID-19-induced nationwide lockdown on children’s behaviour in Punjab, India. *Child Care Health Dev.* 2020, 47, 128–135. [CrossRef] [PubMed]

6. Muhoza, P.; Danovaro-Holliday, M.C.; Diallo, M.S.; Murphy, P.; Sodha, S.V.; Requejo, J.H.; Wallace, A.S. Routine Vaccination Coverage—Worldwide, 2020. *MMWR Morb. Mortal. Wkly. Rep.* 2021, 70, 1495–1500. [CrossRef] [PubMed]

7. Rana, S.; Shah, R.; Ahmed, S.; Mothabbir, G. Post-disruption catch-up of child immunisation and health-care services in Bangladesh. *Lancet Infect. Dis.* 2021, 21, 913. [CrossRef]

8. Mantovani, A.; Rinaldi, E.; Zusi, C.; Beatrice, G.; Saccomani, M.D.; Dalbeni, A. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: A meta-analysis. *Pediatr. Res.* 2020, 89, 733–737. [CrossRef]

9. Kanthimathinathan, H.K.; Dhesi, A.; Hartshorn, S.; Ali, S.H.; Kirk, J.; Nagakumar, P.; Jyothish, D. COVID-19: A UK Children’s Hospital Experience. *Hosp. Pediatr.* 2020, 10, 802–805. [CrossRef]

10. Mehta, N.S.; Mytton, O.T.; Mullins, E.W.S.; Fowler, T.A.; Falconer, C.L.; Murphy, O.B.; Langenberg, C.; Jayatunga, W.J.P.; Eddy, D.H.; Nguyen-Van-Tam, J.S. SARS-CoV-2 (COVID-19): What do we know about children? A systematic review. *Clin. Infect. Dis.* 2020, 71, 2469–2479. [CrossRef] [PubMed]

11. Bhuiyan, M.U.; Stiboy, E.; Hassan, M.Z.; Chan, M.; Islam, M.S.; Haider, N.; Jaffe, A.; Homaira, N. Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis. *Vaccine* 2021, 39, 667–677. [CrossRef]

12. Irfan, O.; Muttalib, F.; Tang, K.; Jiang, L.; Lassi, Z.S.; Bhutta, Z. Clinical characteristics, treatment and outcomes of paediatric COVID-19: A systematic review and meta-analysis. *Arch. Dis. Child. Dev.* 2021, 106, 440–448. [CrossRef] [PubMed]

13. Cui, X.; Zhao, Z.; Zhang, T.; Guo, W.; Guo, W.; Zheng, J.; Zhang, J.; Dong, C.; Na, R.; Zheng, L.; et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). *J. Med. Virol.* 2020, 93, 1057–1069. [CrossRef]

14. Haque, M.; Gowere, M.; Nusrat, N.; Chowdhury, K.; Godman, B. The response to COVID 19 across countries and the implications for future pandemics. *Bangladesh J. Med. Sci.* 2020, 20, 7–14. [CrossRef]

15. Mansourian, M.; Ghandi, Y.; Habibi, D.; Mehrabi, S. COVID-19 infection in children: A systematic review and meta-analysis of clinical features and laboratory findings. *Arch. Pédiatrie* 2021, 28, 242–248. [CrossRef] [PubMed]

16. Islam, M.A.; Kundu, S.; Alam, S.S.; Hossan, T.; Kamal, M.A.; Hassan, R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. *PloS ONE* 2021, 16, e0249788. [CrossRef]

17. Mustafa, Z.U.; Salman, M.; Aldeyab, M.; Kow, C.S.; Hasan, S.S. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. *SN Compr. Clin. Med.* 2021, 3, 1691–1695. [CrossRef]

18. Saini, V.; Jain, C.; Singh, N.; Alsublimani, M.; Gupta, C.; Dar, S.; Haque, S.; Das, S. Paradigm Shift in Antimicrobial Resistance Pattern of Bacterial Isolates during the COVID-19 Pandemic. *Antibiotics* 2021, 10, 954. [CrossRef] [PubMed]

19. Langford, B.J.; So, M.; Raybardown, S.; Leung, V.; Westwood, D.; MacFadden, D.R.; Soucy, J.-P.R.; Daneman, N. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. *Clin. Microbiol. Infect.* 2020, 26, 1622–1629. [CrossRef]

20. Langford, B.J.; So, M.; Raybardown, S.; Leung, V.; Soucy, J.-P.R.; Westwood, D.; Daneman, N.; MacFadden, D.R. Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis. *Clin. Microbiol. Infect.* 2021, 27, 520–531. [CrossRef]
22. Grau, S.; Hernández, S.; Echeverría-Esnal, D.; Almedral, A.; Ferrer, R.; Limón, E.; Horcajada, J.P.; On behalf of the Catalan Infection Control Antimicrobial Stewardship Program. Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. *Antibiotics* 2021, *10*, 943. [CrossRef] [PubMed]

23. Molla, M.A.; Yeasmin, M.; Islam, K.; Sharif, M.; Amin, R.; Nafisa, T.; Ghosh, A.K.; Parveen, M.; Arif, M.H.; Alam, J.A.J.; et al. Antibiotic Prescribing Patterns of COVID-19 Dedicated Wards in Bangladesh: Findings from a Single Center Study. *Infect. Prev. Pract.* 2021, *3*, 100134. [CrossRef] [PubMed]

24. Mah-E-Muneer, S.; Hassan, Z.; Biswas, A.A.; Rahman, F.; Akhtar, Z.; Das, P.; Islam, A.; Chowdhury, F. Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic. *Antibiotics* 2021, *10*, 738. [CrossRef]

25. Hofer, U. The cost of antimicrobial resistance. *Nat. Rev. Genet.* 2018, *17*, 3. [CrossRef]

26. Founou, R.C.; Founou, L.L.; Essack, S.Y. Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. *PLoS ONE* 2017, *12*, e0189621. [CrossRef]

27. Cassini, A.; Högborg, L.D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G.S.; Colomb-Cotinat, M.; Kretzschmar, M.E.; Devleeschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. *Lancet Infect. Dis.* 2019, *19*, 56–66. [CrossRef]

28. Godman, B.; Egwuenu, A.; Haque, M.; Malande, O.; Schellack, N.; Kumar, S.; Saleem, Z.; Sneddon, J.; Hoxha, I.; Islam, S.; et al. Strategies to Improve Antimicrobial Utilisation with a Special Focus on Developing Countries. *Life* 2021, *11*, 528. [CrossRef]

29. Haque, M.; Meyer, J.C.; Godman, B. Potential ways to address antimicrobial resistance across India and wider exacerbated by COVID-19. *J. Appl. Pharm. Sci.* 2021, *11*, i–vii. [CrossRef]

30. Hsu, J. How COVID-19 is accelerating the threat of antimicrobial resistance. *BMJ* 2020, *369*, m383. [CrossRef]

31. Adebisi, Y.A.; Alaran, A.J.; Okereke, M.; Oke, G.I.; Amos, O.A.; Olaoye, O.C.; Oladunjoye, I.; Olanrewaju, A.Y.; Ukor, N.A.; et al. Antibiotic Use and Resistance at COVID-19 Dedicated Wards in Bangladesh: Findings from a Single Center Study. *Antibiotics* 2021, *10*, 837–848. [CrossRef]

32. Majumder, A.A.; Rahman, S.; Cohall, D.; Bharatha, A.; Singh, K.; Haque, M.; Hilaire, M.G.S. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. *Infect. Drug Resist.* 2020, *13*, 4713–4738. [CrossRef]

33. Ahmed, I.; Rabbi Md, B.; Sultana, S. Antibiotic resistance in Bangladesh: A systematic review. *Int. J. Infect. Dis.* 2019, *80*, 54–61. [CrossRef] [PubMed]

34. Global Antibiotic Resistance Partnership—Bangladesh, GARP-Bangladesh National Working Group. Antibiotic Use and Resistance in Bangladesh—Situational Analysis and Recommendations. 2018. Available online: https://cddep.org/wp-content/uploads/2018/08/ANTIBIOTIC-USE-RESISTANCE-IN_BD_2018.pdf (accessed on 1 December 2021). [CrossRef]

35. Nusrat, T.; Akter, N.; A Rahman, N.A.; Godman, B.; Rozario, D.T.D.; Haque, M. Antibiotic resistance and sensitivity pattern of Metallo-β-Lactamase Producing Gram-Negative Bacilli in ventilator-associated pneumonia in the intensive care unit of a public medical hospital in Bangladesh. *Hosp. Pract.* 2020, *48*, 128–136. [CrossRef] [PubMed]

36. Haque, M.; Godman, B. Potential Strategies to Improve Antimicrobial Utilisation in Hospitals in Bangladesh Building on Experiences Across Developing Countries. *Bangladesh J. Med. Sci.* 2021, *20*, 469–477. [CrossRef]

37. Mardi, P.; Esmaeili, M.; Iravani, M.; Abdar, M.E.; Pourrostami, K.; Qorbani, M. Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review. *Front. Pediatr.* 2021, *9*, 625377. [CrossRef]

38. Yasuhara, J.; Watanabe, T.; Takagi, H.; Sumitomo, N.; Kuno, T. COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis. *Pediatr. Pulmonol.* 2021, *56*, 837–848. [CrossRef]

39. Hobbs, C.V.; Khaitan, A.; Kirmse, B.M.; Borkowsky, W. COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes. *Front. Pediatr.* 2020, *8*, 593455. [CrossRef]

40. WHO. Discontinues Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19. Available online: https://www.who.int/news-room/detail/04-07-2020-who-discotinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 (accessed on 10 October 2021). [CrossRef]

41. Horby, P.W.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Emerson, J.; Palfreeman, A.; Raw, J.; Elmahi, E.; Prudon, B.; et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. *Lancet* 2020, *396*, 1345–1352. [CrossRef]

42. Gil Martínez, V.; Salas, A.A.; Ballestín, S.S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. *Pharmaceuticals* 2021, *14*, 736. [CrossRef]

43. The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. *N. Engl. J. Med.* 2020, *383*, 2030–2040. [CrossRef] [PubMed]

44. Dyer, O. COVID-19: Remdesivir has little or no impact on survival, WHO trial shows. *BMJ* 2020, *371*, m4057. [CrossRef] [PubMed]

45. Charan, J.; Kaur, R.J.; Bharwardj, P.; Haque, M.; Sharma, P.; Misra, S.; Godman, B. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. *Exp. Rev. Clin. Pharmacol.* 2020, *14*, 95–103. [CrossRef] [PubMed]

46. Abubakar, A.R.; Sani, I.H.; Godman, B.; Kumar, S.; Islam, S.; Jahan, I.; Haque, M. Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. *Infect. Drug Resist.* 2020, *13*, 4673–4695. [CrossRef] [PubMed]

47. Wadvalla, B.-A. COVID-19: Ivermectin’s politicisation is a warning sign for doctors. *BMJ* 2021, *373*, n747. [CrossRef] [PubMed]
95. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436. [CrossRef] [PubMed]
96. Sharland, M.; Gandra, S.; Huttner, B.; Moja, L.; Pulcini, C.; Zeng, M.; Mendelson, M.; Cappello, B.; Cooke, G.; Magrini, N.; et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect. Dis. 2019, 19, 1278–1280. [CrossRef]
97. Hsia, Y.; Sharland, M.; Jackson, C.; Wong, I.C.K.; Magrini, N.; A Bielicki, J. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: An analysis of sales data from 70 middle-income and high-income countries. Lancet Infect. Dis. 2018, 19, 67–75. [CrossRef]
98. Van den Bosch, C.M.; Hulscher, M.E.; Akkermans, R.P.; Wille, J.; Geerlings, S.E.; Prins, J.M. Appropriate antibiotic use reduces length of hospital stay. J. Antimicrob. Chemother. 2016, 72, 923–932. [CrossRef]
99. Cyriac, J.M.; James, E. Switch over from intravenous to oral therapy: A concise overview. J. Pharmacoel. Pharmacother. 2014, 5, 83–87. [CrossRef] [PubMed]
100. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021, 384, 693–704. [CrossRef]
101. Kumar, P.; Kumar, M.; Bedi, O.; Gupta, M.; Kumar, S.; Jaiswal, G.; Rahi, V.; Yedke, N.G.; Bijalwan, A.; Sharma, S.; et al. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology 2021, 29, 1001–1016. [CrossRef]
102. Milani, G.; Macchi, M.; Guz-Mark, A. Vitamin C in the Treatment of COVID-19. Nutrients 2021, 13, 1172. [CrossRef]
103. Versporten, A.; Zarb, P.; Caniaux, I.; Gros, M.-F.; Drapier, N.; Miller, M.; Jarlier, V.; Nathwani, D.; Goossens, H.; Koraqi, A.; et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. Lancet Glob. Health 2018, 6, e619–e629. [CrossRef]
104. Niaz, Q.; Godman, B.; Campbell, S.; Kibuule, D. Compliance to prescribing guidelines among public health care facilities in Sub-Saharan Africa and Suggestions for the Future. J. Biomed. Pharm. Sci. 2021, 4, 88–95. [CrossRef]
105. Nakwatumbah, S.; Kibuule, D.; Godman, B.; Haakuria, V.; Kalemeera, F.; Baker, A.; Mubita, M.; Mwangana, M. Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia’s national referral hospital: A pilot study and the implications. Exp. Rev. Anti-Infect. Ther. 2017, 15, 713–721. [CrossRef] [PubMed]
106. Olaru, I.D.; Meierkord, A.; Godman, B.; Ngwenya, C.; Fitzgerald, F.; Dondo, V.; Ferrand, R.A.; Kranzer, K. Assessment of antimicrobial use and prescribing practices among pediatric inpatients in Zimbabwe. J. Chemother. 2020, 32, 456–459. [CrossRef] [PubMed]
107. Sefah, I.A.; Essah, D.O.; Kurdi, A.; Sneddon, J.; Alalbila, T.M.; Kordorwu, H.; Godman, B. Assessment of adherence to pneumonia guidelines and its determinants in an ambulatory care clinic in Ghana: Findings and implications for the future. JAC-Antimicrob. Resist. 2021, 3, dlab080. [CrossRef] [PubMed]
108. Gitaka, J.; Kamita, M.; Mureithi, D.; Ndewa, D.; Masika, M.; Omuse, G.; Ngari, M.; Makokha, F.; Mwaura, P.; Mathai, R.; et al. Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: A protocol for an implementation science approach. BMJ Open 2020, 10, e030823. [CrossRef] [PubMed]
109. Campbell, S.M.; Meyer, J.C.; Godman, B. Why Compliance to National Prescribing Guidelines is Important Especially across Sub-Saharan Africa and Suggestions for the Future. J. Biomed. Pharm. Sci. 2021, 4, 309. [CrossRef]
110. MacBride-Stewart, S.; McTaggart, S.; Kurdi, A.; Sneddon, J.; McBurney, S.; Nascimento, R.C.R.M.; Mueller, T.; Kwon, H.Y.; Morton, A.; Seaton, R.A.; et al. Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global implications of drug prescriptions. Int. J. Clin. Exp. Med. 2021, 14, 2563–2586. [CrossRef]
111. Godman, B.; Fadare, J.; Kwon, H.-Y.; Dias, C.Z.; Kurdi, A.; Godoi, I.P.D.; Kibuule, D.; Hoxha, I.; OPGA, S.; Saleem, Z.; et al. Evidence-based public policy making for medicines across countries: Findings and implications for the future. J. Comp. Eff. Res. 2021, 10, 1019–1052. [CrossRef]
112. Dlamini, N.N.; Meyer, J.C.; Kruger, D.; Kurdi, A.; Godman, B.; Schellack, N. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. Hosp. Pract. 2019, 47, 88–95. [CrossRef] [PubMed]